Artiva Biotherapeutics, Inc.
ARTV
$2.47
$0.020.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | -- | -- | 251.00K | 2.35M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | -- | -- | 251.00K | 2.35M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00 | -- | -- | 251.00K | 2.35M |
| SG&A Expenses | 4.95M | 4.81M | 3.86M | 3.59M | 3.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.27M | 18.34M | 16.19M | 14.74M | 14.32M |
| Operating Income | -18.27M | -18.34M | -16.19M | -14.49M | -11.97M |
| Income Before Tax | -16.10M | -17.47M | -17.84M | -13.96M | -11.93M |
| Income Tax Expenses | -- | -- | -- | -- | 72.00K |
| Earnings from Continuing Operations | -16.10M | -17.47M | -17.84M | -13.96M | -12.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.10M | -17.47M | -17.84M | -13.96M | -12.00M |
| EBIT | -18.27M | -18.34M | -16.19M | -14.49M | -11.97M |
| EBITDA | -17.65M | -17.71M | -15.59M | -13.91M | -11.38M |
| EPS Basic | -0.66 | -0.92 | -22.00 | -17.24 | -14.82 |
| Normalized Basic EPS | -0.89 | -0.58 | -13.75 | -10.78 | -18.77 |
| EPS Diluted | -1.32 | -0.92 | -22.00 | -17.24 | -29.65 |
| Normalized Diluted EPS | -0.89 | -0.58 | -13.75 | -10.78 | -18.77 |
| Average Basic Shares Outstanding | 24.39M | 18.90M | 811.20K | 809.80K | 809.40K |
| Average Diluted Shares Outstanding | 24.39M | 18.90M | 811.20K | 809.80K | 809.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |